If you have been reading about HPLC-MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-22. Numbers and descriptions here follow the published literature rather than marketing material.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
== Medical uses == Injectable fillers are widely used in cosmetics for soft tissue augmentation and facial rejuvenation. Their primary clinical applications include the correction of facial wrinkles and folds, restoration of age-related volume loss, and the enhancement of facial contours such as the lips, cheeks, and jawline. Hyaluronic acid-based fillers are commonly used for superficial and mid-dermal injections to treat fine lines and improve skin hydration, while more robust fillers are injected into deeper tissue layers to correct severe wrinkles and provide structural support. Biodegradable fillers, such as poly(lactic acid), can stimulate collagen production, contributing to longer-term volume effects. Injectable hydrogel-based fillers have been investigated for a wide range of medical applications due to their biocompatibility, injectability, and ability to form three-dimensional networks in situ. In wound healing, these materials provide a moist environment, act as barriers against infection, and conform to irregular tissue defects, thereby promoting tissue regeneration. They are also used to prevent post-operative adhesions by acting as physical barriers that separate tissues during healing, reducing fibrotic attachment. In hemostasis, injectable hydrogels can rapidly solidify at bleeding sites and adhere to tissues, enabling effective control of hemorrhage.
The mechanism of action is explained below: a) Application of acid to dentin will result in partial/total removal of smear layer and demineralization of the dentin. b) Acid will demineralize the intertubular and peritubular dentin, and then open the dentinal tubules while exposing the collagen fibres, hence increasing the microporosity of intertubular dentin. c) Dentin will be demineralized by up to approximately 7.5 μmeter, depending on the type of acid used, time of application and concentration. d) Primer system is designed to increase critical surface tension of dentin, which gets decreased after etching of acid. e) Bonding mechanism is when:
==== Corneal retention and permeability in topical drug delivery to the eye ==== The majority of ocular therapeutic agents are administered to the eye via the topical route. Cornea is one of the main barriers for drug diffusion because of its highly impermeable nature. Its continuous irrigation with a tear fluid also results in poor retention of the therapeutic agents on the ocular surface. Poor permeability of the cornea and quick wash out of therapeutic agents from ocular surface result in very low bioavailability of the drugs administered via topical route (typically less than 5%). Poor retention of formulations on ocular surfaces could potentially be improved with the use of mucoadhesive polymers. Drug permeability through the cornea could be facilitated with addition of penetration enhancers into topical formulations.
Sources: en.wikipedia.org
(2026) present a dataset of ages obtained through radiocarbon dating by accelerator mass spectrometry of bone collagen from remains of late Quaternary mammalian megafauna from Eurasia and North America. Review of advances in the study of paleogenomics of Chinese Quaternary proboscideans, even- and odd-toed ungulates and large carnivorans from the preceding years is published by Sheng et al. (2026). Köhler (2026) reviews the evolution of traits of organims from inland environments (including extinct Myotragus) that are adaptations to life in low-mortality isolated ecosystems with limited resources, and notes similarities with the evolution of traits of organisms adapted to life in caves. Schowanek et al. (2026) study factors influencing survival probability of mammals living in tropical forests of Africa, the Americas and the Indomalayan realm during the past 130,000 years, and report that analyses utilizing different statistical models recover similar predictors of extinction risk at the global scale, but recover variable predictors of extinction risk at smaller spatial scales. Kennedy & Sumanarathna (2026) present the first three-dimensional palaeoart reconstructions of Palaeoloxodon namadicus sinhaleyus and the Quaternary rhinoceros from the Sabaragamuwa Basin (Sri Lanka) historically referred to as Rhinoceros sinhaleyus. Faria et al.
== Target == Do6a primarily targets Pickpocket/Balboa (Ppk/Bba or Ppk1/Ppk26) ion channels that are evenly distributed on the dendrites of class IV dendritic arborizing (cIV da) neurons in the peripheral nervous system of fruit fly larvae. cIV da neurons are responsible specifically for nociception from mechanical stimuli and heat, unlike cI, cII cIII that respond to other sensory input, like proprioception or gentle touch. These neurons have highly complex dendritic trees and blocking their synaptic output significantly reduces behavioral nociceptive responses (e.g. rolling) in larvae. Do6a appears to target exclusively insect nociceptors, likely due to the parasitic reproduction cycle of the species requiring good protection against other insects. Other peptides in the venom (e.g. Do10a and Do13a) affect pain receptors in mammals. Expression of both Ppk and Bba forming a heteromeric channel complex in cIV da neurons are necessary for nociception from Do6a. Ppk/Bba belong to Degenerin/Epithelial (DEG/ENaC) protein family and respond specifically to mechanical nociception and not noxious heat. Gating of these channels is still not entirely understood. While their activation upon harsh mechanical pressure may suggest a mechanosensitive nature of these channels, peptides like Do6a and Vulnusin have been shown to activate Ppk1/Ppk26 without a presence of a mechanical stimulus, pointing towards ligand-gating instead.
== Research == Since 2009 the Foundation has sponsored numerous clinical trials conducted by the Waterford Institute of Technology, and has funded numerous Fellowships, the principal bequest being a Chair in Human Nutrition funded permanently by it from October 2016, the current holder being Professor John Nolan PhD.
Sources: en.wikipedia.org
Glargine and detemir are significantly more expensive than NPH, lente and ultralente, and they cannot be mixed with other forms of insulin. A short-acting insulin is used to simulate the endogenous insulin surge produced in anticipation of eating. Regular insulin, lispro, aspart and glulisine can be used for this purpose. Regular insulin should be given with about a 30-minute lead-time prior to the meal to be maximally effective and to minimize the possibility of hypoglycemia. Lispro, aspart and glulisine are approved for dosage with the first bite of the meal, and may even be effective if given after completing the meal. The short-acting insulin is also used to correct hyperglycemia.
However, the commission concluded that an attack on Russian peacekeepers was not "a sufficient condition" to be used for self-defence by Russia and "the fact of the Georgian attack on the Russian peacekeepers’ basis could not be definitely confirmed by the mission." The commission said that Russian peacekeepers had the right to immediate, necessary and proportionate response in case of direct attack on them. However, "doubts remain whether the Russian peacekeepers were attacked in the first place," and the mission "was unable to establish whether, at the time of the alleged attacks on Russian peacekeepers’ bases, the peacekeepers had lost their protection owing to their participation in the hostilities." The commission concluded that "the expulsion of the Georgian forces from South Ossetia, and the defence of South Ossetia as a whole was not a legitimate objective", and "according to international law, the Russian military action taken as a whole was therefore neither necessary nor proportionate to protect Russian peacekeepers in South Ossetia." The commission concluded that Russia did not have the right to justify its actions as "a mere reinforcement and fulfilment of its peacekeeping mission." The commission concluded that the South Ossetian separatists "could not validly invite Russia to support them" militarily and Russian military action could not be justified as intervention in a civil war.
A 2025 review highlights relevant candidates in the current antibiotic development pipeline and discusses alternative strategies, including phage therapy and immunotherapeutics, for the treatment of multidrug-resistant enterococci.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.